NCT04948918 (REFRAIN) is a NA clinical trial of Anatomically optimized distal renal denervation in Type 2 Diabetes Mellitus, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

Who is sponsoring NCT04948918?

NCT04948918 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

What drugs are being tested in NCT04948918?

Interventions in NCT04948918: Anatomically optimized distal renal denervation.

What condition does NCT04948918 study?

NCT04948918 studies Type 2 Diabetes Mellitus, Hypertension.

Is NCT04948918 still recruiting?

NCT04948918 is currently completed. Last updated 29 November 2023.

Last reviewed 2023-11-29 · How we verify

NCT04948918: REFRAIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Distal Renal Denervation to Prevent Renal Function Decline in Patients With T2DM and Hypertension

Completed NA Last updated 29 November 2023

What this trial tests

NA trial testing Anatomically optimized distal renal denervation in Type 2 Diabetes Mellitus in 29 participants. Completed in 20 September 2023.

Timeline

20 September 2020

Primary endpoint
20 September 2022

20 September 2023

Quick facts

Lead sponsor	Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	20 September 2020
Primary completion	20 September 2022
Estimated completion	20 September 2023
Sites	1 location across Russia

Drugs / interventions tested

Anatomically optimized distal renal denervation

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Hypertension — all drugs for Hypertension →

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Who can join

Adults 20 to 80, any sex, with Type 2 Diabetes Mellitus or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to test the hypothesis that distal renal denervation (RDN) may delay or prevent the progressive decline of renal function in patients with type 2 diabetes mellitus and hypertension

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Lipocalin 2-not only a biomarker: a study of current literature and systematic findings of ongoing clinical trials.
Asaf S, Maqsood F, Jalil J, Sarfraz Z, et al · · 2023 · cited 38× · PMID 36529828 · DOI 10.1007/s12026-022-09352-2
Renal Safety of Distal Renal Denervation on Kidney Function in Diabetic Patients with Resistant Hypertension.
Manukyan M, Mordovin V, Pekarskiy S, Zyubanova I, et al · · 2026 · PMID 41752674 · DOI 10.3390/medicina62020274
Renal Safety of Distal Renal Denervation on Kidney Function in Diabetic Patients with Resistant Hypertension
· 2026
Favorable Effect of Distal Renal Denervation on Kidney Function in Diabetic Patients with Resistant Hypertension
Manukyan M, Mordovin V, Pekarsky S, Zyubanova I, et al · · 2025 · DOI 10.20944/preprints202511.0311.v1

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Tomsk National Research Medical Center of the Russian Academy of Sciences trials

Trials by the same sponsor.

NCT07457541 — Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI · Phase 1 · active not recruiting
NCT07475390 — 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging · NA · active not recruiting
NCT07292571 — Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 · Phase 2 · enrolling by invitation
NCT07275463 — [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression · Phase 2 · enrolling by invitation
NCT07018895 — Personalized Hypoxic-hyperoxic Preconditioning in Elderly People · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04948918 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tomsk National Research Medical Center of the Russian Academy of Sciences
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04948918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing